Pharmacologic treatment of panic disorder

Current Topics in Behavioral Neurosciences

Volumn 2, Issue , 2010, Pages 469-485

  Stein, Murray ^a   Steckler, Thomas ^a   Lightfoot, Jeffrey D ^a   Hay, Elizabeth ^a   Goddard, Andrew W ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety; Benzodiazepine; Panic; Pharmacology; SNRI; SSRI; TCA; Treatment

Indexed keywords

ALPRAZOLAM; ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; CITALOPRAM; CLONAZEPAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PHENELZINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE; 4 AMINOBUTYRIC ACID; BENZODIAZEPINE DERIVATIVE; SEROTONIN;

ANTIDEPRESSANT ACTIVITY; ARTICLE; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG CHOICE; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG TOLERANCE; DRUG TREATMENT FAILURE; HUMAN; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RISK BENEFIT ANALYSIS; ANXIETY; BEHAVIOR THERAPY; METABOLISM; REVIEW; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY; BEHAVIOR THERAPY; BENZODIAZEPINES; GAMMA-AMINOBUTYRIC ACID; HUMANS; MONOAMINE OXIDASE INHIBITORS; PANIC DISORDER; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 79952257738     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2009_35     Document Type: Article

References (93)

1. Abelson JL, Curtis GC (1996) Hypothalamic-pituitary-adrenal axis activity in panic disorder: prediction of long-term outcome by pretreatment cortisol levels. Am J Psychiatry 153(1):69-73
2. American Psychiatric Association (2009) Practice guideline for the treatment of persons with disorder, 2nd edn. American Psychiatric Association, Washington, DC
3. Asnis GM, Hameedi FA et al (2001) Fluvoxamine in the treatment of panic disorder: a multicenter, double-blind, placebo-controlled study in outpatients. Psychiatry Res 103(1):1-14
4. Barlow DH, Gorman JM et al (2000) Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 283(19):2529-2536
5. Berigan TR, Casas A et al (1998) Nefazodone and the treatment of panic. J Clin Psychiatry 59 (5):256-257
6. Blier P (2001) Pharmacology of rapid-onset antidepressant treatment strategies. J Clin Psychiatry 62(Suppl 15):12-27
7. Blier P, Abbott FV (2001) Putatuve mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J Psychiatry Neurosci 26:37-43
8. Boyer W (1995) Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 10(1):45-49
9. Bystritsky A, Rosen R et al (1999) Pilot open-label study of nefazodone in panic disorder. Depress Anxiety 10(3):137-139
10. Canadian Psychiatric Association (2006) Clinical practice guidelines: management of anxiety disorders. Can J Psychiatry 51:275-277
11. Carpenter LL, Leon Z et al (1999) Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry 11(2):81-86
12. Cottraux J, Note ID et al (1995) A controlled study of congnitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. Br J Psychiatry 167:635-641
13. Coupland NJ, Bell CJ et al (1996) Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 16(5):356-362
14. Cross-National and S. Group (1992) Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators [published erratum appears in Br J Psychiatry 1992 Nov;161:724] [see comments]. Br J Psychiatry 160:191-202; discussion 202-205
15. Curtis CG, Massana J et al (1993) Maintenance drug therapy of panic disorder. J Psychiatr Res 27 (Suppl 1):127-142
16. Dager SR, Roy-Byrne P et al (1992) Long-term outcome of panic states during double-blind treatment and after withdrawal of aprazolam and placebo. Ann Clin Psychiatry 4:251-258
17. Dannon PN, Iancu I et al (2002) The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study. Hum Psychopharmacol 17(7):329-333
18. Fava M (2006) Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry 67(Suppl 4):14-21
19. Fisher AA, Davis MW (2002) Serotonin syndrome caused by selective serotonin reuptakeinhibitors-metoclopramide interaction. Ann Pharmacother 36(1):67-71
20. Goddard AW, Gorman JM et al (1998) Neurobiology of panic disorder. In: Rosenbaum J, Pollack M (eds) Panic disorder and its treatment. Marcel Dekker, Inc, New York, pp 57-92
21. Goddard AW, Brouette T et al (2001) Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 58(7):681-686
22. Gorman JM, Kent JM (1999) SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. J Clin Psychiatry 60(Suppl 4):33-38, discussion 39
23. Haas CK, Shekhar A et al (2009) Anxiety Drug Therapy. Encyclopedia of Neuroscience 499-508
24. Hirschmann D, Dannon PN et al (2000) Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 20:556-559
25. Hollifield M, Thompson PM et al (2005) Potential effectiveness and safety of olanzapine in refractory panic disorder. Depress Anxiety 21:33-40
26. Howland RH (1996) Induction of mania with serotonin reuptake inhibitors. J Clin Psychopharmacol 16(6):425-427
27. Jefferson JW (1997) Antidepressants in panic disorder. J Clin Psychiatry 58(Suppl 2):20-24, discussion 24-25
28. Jefferson JW (2001) Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder). J Clin Psychiatry 62(Suppl 1):50-53
29. Johnson PL, Truitt W et al (2009) A key role for orexin in panic anxiety. Nat Med 16:111-115
30. Kessler RC, McGonagle KA et al (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51:8-19
31. Krystal JH, D'Souza DC et al (2001) Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorders. Med Clin North Am 85(3):559-577
32. Leinonen E, Lepola U et al (2000a) Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. J Psychiatry Neurosci 25(1):25-32
33. Leinonen E, Lepola U et al (2000b) Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. J Psychiatry Neurosci 25:24-32
34. Liebowitz MR, Hollander E et al (1990) Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatr Scand Suppl 360:29-34
35. Londborg PD, Wolkow R et al (1998) Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 173:54-60
36. Louie AK, Lewis TB et al (1993) Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 54:435-438
37. Mancama D, Kerwin RW (2003) Role of pharmacogenomics in individualizing treatment with SSRI's. CNS Drugs 17(3):143-151
38. Mavissakalian MR, Perel JM (1994) Dose-response characterization of the antipanic effects of imipramine. Psychopharmacol Bull 30(2):171-174
39. Mavissakalian MR, Perel JM (2001) 2nd year maintenance and discontinuation of imipramine in panic disorder with agoraphobia. Ann Clin Psychiatry 13(2):63-67
40. McHugh RK, Smits JAJ et al (2009) Empirically supported treatments for panic disorder. Psychiatr Clin North Am 32:593-610
41. Michelson D, Allgulander C et al (2001) Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. Br J Psychiatry 179:514-518
42. Misri S, Burgmann A et al (2000) Are SSRIs safe for pregnant and breastfeeding women? Can Fam Physician 46(626-628):631-633
43. Moroz G, Rosenbaum JF (1999) Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. J Clin Psychiatry 60:604-612
44. Munjack DJ, Crocker B et al (1989) Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 9:22-27
45. Murphy TK, Bengtson MA et al (2000) Selective serotonin reuptake inhibitors in the treatment of paediatric anxiety disorders: a review. Int Clin Psychopharmacol 15(Suppl 2):S47-S63
46. Noyes R, Burrows GD et al (1996) Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry 57:349-355
47. Otto MW, Tuby KS et al (2001) An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry 158(12):1989-1992
48. Pande AC, Pollack MH et al (2000) Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 20:467-471
49. Perna G, Bertani A et al (2001) A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry 34(3):85-90
50. Pitman RK, Sanders KM et al (2002) Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 51(2):189-192
51. Plotsky P, Owens M et al (1995) Neuropeptide alterations in mood disorders. In: Bloom F, Kupfer D (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York, pp 971-982
52. Pohl RB, Wolkow RM et al (1998) Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry 155(9):1189-1195
53. Pollack MH, Worthington JJ et al (1997) Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. J Clin Psychiatry 58(Suppl 11):19-23
54. Pollack MH, Otto MW et al (1998) Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 55(11):1010-1016
55. Pollack MH, Simon NM et al (2003) Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 17:276-282
56. Rapaport MH, Wolkow R et al (2001) Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand 104(4):289-298
57. Ravaris CL, Friedman MJ et al (1991) A controlled study of alprazolam and propranolol in panicdisordered and agoraphobic outpatients. J Clin Psychopharmacol 11:344-350
58. Reinscheid RK (2008) Neuropeptide S: anatomy, pharmacology, genetics and physiological functions. Results Probl Cell Differ 46:145-158
59. Reul JM, Labeur MS et al (1994) Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 60(5):509-519
60. Robins LN, Helzer JE et al (1984) Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 41:949-958
61. Rosenbaum JF, Pollock RA et al (1996) The pharmacotherapy of panic disorder. Bull Menninger Clin 60(Suppl A):A54-A75
62. Rotondo A, Mazzanti C et al (2002) Catechol o-methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder patients with and without comorbid panic disorder. Am J Psychiatry 159(1):23-29
63. Royal Australian and New Zealand College of Psychiatrists (2003) Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Aust N Z J Psychiatry 37:641-656
64. Roy-Byrne PP, Clary CM et al (2001) The effect of selective serotonin reuptake inhibitor treatment of panic disorder on emergency room and laboratory resource utilization. J Clin Psychiatry 62(9):678-682
65. Roy-Byrne PP, Craske MG, Stein MB (2006) Panic disorder. Lancet 368:1023-1032
66. Rupprecht R, Rammes G et al (2009) Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 325:490-493
67. Savoldi F, Somenzini G et al (1990) Etizolam versus placebo in the treatment of panic disorder with agoraphobia: a double-blind study. Curr Med Res Opin 12:185-190
68. Schmitt U, Hiemke C (1999) Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze. Behav Pharmacol 10(2):131-137
69. Schweizer E, Clary C et al (1992) The use of low-dose intranasal midazolam to treat panic disorder: a pilot study. J Clin Psychiatry 53:19-22
70. Schweizer E, Rickels K et al (1993) Maintenance drug treatment of panic disorder: I. results of a prospective, placebo-controlled comparison of aprazolam and Imipramine. Arch Gen Psychiatry 50:51-60
71. Selak I (2001) Pregabalin (Pfizer). Curr Opin Invest Drugs 2(6):828-834
72. Sheehan DV, Raj AB et al (1993) The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 88:1-11
73. Sheikh JI, Lonborg P et al (2000) The efficacy of sertraline in panic disorder: combined results from two fixed-dose studies. Int Clin Psychopharmacol 15:335-342
74. Shekhar A, Keim SR (2000) LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology 39 (7):1139-1146
75. Shelton RC (2006) The nature of discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry 67(Suppl 4):3-7
76. Simon NM, Hoge EA et al (2006) An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry 67:381-385
77. Stein MB (2005) Anxiety disorders: somatic treatment. In: Kaplan HI, Sadock BJ (eds) Comprehensive textbook of psychiatry. Lippincott, Williams, & Wilkins, Philadelphia, PA
78. Stein MB, Sareen J et al (2001) Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 158(10):1725-1727
79. Stein MB, Kline NA et al (2002) Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 159(10):1777-1779
80. Szabo ST, Blier P (2001) Effects of chronic antidepressant drug administration and electroconvulsive shock on locus coeruleus electrophysiologic activity. Biol Psychiatry 50(8):644-646
81. Szabo ST, de Montigny C et al (2000) Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int J Neuropsychopharmacol 3(1):1-11
82. Tesar GE, Rosenbaum JF et al (1991) Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 52:69-76
83. Tiller JW, Bouwer C et al (1999) Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psychiatry Clin Neurosci 249(Suppl 1):S7-S10
84. Tiwari AK, Souza RP et al (2009) Pharmacogenetics of anxiolytic drugs. J Neural Transm 116:667-677
85. Tucker P, Adamson P et al (1997) Paroxetine increases heart rate variability in panic disorder. J Clin Psychopharmacol 17(5):370-376
86. Valenca AM, Nardi AE et al (2003) Therapeutic response to benzodiazepine in panic disorder subtypes. Sao Paulo Med J 121:77-80
87. van Vliet IM, Westenberg HG et al (1993) MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study. Psychopharmacology (Berl) 112(4):483-489
88. Versiani M, Cassano G et al (2002) Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 63(1):31-37
89. Walker DL, Ressler KJ et al (2002) Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci 22(6):2343-2351
90. Weintrob N, Cohen D et al (2002) Decreased growth during therapy with selective serotonin reuptake inhibitors. Arch Pediatr Adolesc Med 156(7):696-701
91. Weissman MM, Markowitz JS et al (1990) Panic disorder and cardiovascular/cerebrovascular problems: results from a community survey [see comments]. Am J Psychiatry 147:1504-1508
92. Woodman CL, Noyes R Jr (1994) Panic disorder: treatment with valproate. J Clin Psychiatry 55:134-136
93. Zwanzger P, Eser D et al (2009) Changes in CCK-4 induced panic after treatment with the GABAreuptake inhibitor tiagabine are associated with an increase in 3ά, 5ά-tetrahydrodeoxycorticosterone concentrations. Psychoneuroendocrinology 34:1586-1589